Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05027867 · ClinicalTrials.gov registry record · Phase 2
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Phase 2 study, sponsored by Kartos Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT05027867 is a Phase 2 study that was terminated before completion, run by Kartos Therapeutics. The registered enrollment target is 3 participants.
The verdict
NCT05027867, a Phase 2 study, was terminated before completion, sponsored by Kartos Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with relapsed or refractory small cell lung cancer. This study will be conducted in 2 parts. Part 1 will evaluate two treatment arms, each with a different KRT-232 dose. Part 2 will continue the evaluation of the selected treatment arms from Part 1.
Interventions
- DRUG KRT-232
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-12-06 |
| Est. Completion | 2022-08-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05027867
The ClinicalTrials.gov registry entry for NCT05027867 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kartos Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KRT-232 is the first listed.
NCT05027867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05027867 about?
NCT05027867 is a clinical study titled "KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer". This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with relapsed or refractory small cell lung cancer. This study will be conducted in 2 parts. Part 1 will evaluate two treatment arms, each with a different KRT-232 dose. Part 2 will continue t...
What is the current status of trial NCT05027867?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2021-12-06. Estimated completion is 2022-08-26.
What interventions are being tested in trial NCT05027867?
The interventions under investigation include: KRT-232 (DRUG).
Who is sponsoring clinical trial NCT05027867?
This trial is sponsored by Kartos Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.